ARIAD Pharmaceuticals
ARIAD is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD8.0b (Public information from Jan 2017)
Cambridge Massachusetts (HQ)
Financials
Estimates*
EUR | 2015 |
---|---|
R&D budget | 152m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$46.0m | Early VC | ||
N/A | N/A | IPO | |
N/A | $8.0m | Post IPO Equity | |
N/A | $6.1m | Post IPO Equity | |
$10.0m | Post IPO Equity | ||
N/A | $41.0m | Post IPO Equity | |
N/A | $9.4m | Post IPO Equity | |
$14.0m | Post IPO Equity | ||
$5.2b Valuation: $5.2b | Acquisition | ||
Total Funding | AUD71.1m |
Related Content
Recent News about ARIAD Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by ARIAD Pharmaceuticals
EditACQUISITION by Concentra Biosciences Dec 2023